J Stroke.  2024 Sep;26(3):349-359. 10.5853/jos.2024.02670.

Patent Foramen Ovale and Other Cardiopathies as Causes of Embolic Stroke With Unknown Source

• Kim JS

• KMID: 2559554
• DOI: http://doi.org/10.5853/jos.2024.02670

Abstract

In patients with stroke caused by cardiac embolism, the responsible heart diseases include atrial fibrillation, acute myocardial infarction, sick sinus syndrome, valvular disease, and significant heart failure. When there is no clear source of the embolism, the condition is referred to as “embolic stroke with unknown source (ESUS).” Recent studies have shown that the most common cause of ESUS is a right-to-left cardiac shunt through a patent foramen ovale (PFO). However, considering that PFOs are found in up to 25% of the general population, their presence does not necessarily indicate causality. In patients with ESUS associated with a PFO, either anticoagulants or antiplatelets are used for the prevention of future strokes or transient ischemic attacks. However, it currently remains unclear which treatment is superior. Nevertheless, recent randomized clinical trials have shown that percutaneous closure of the PFO more effectively reduces the incidence of recurrent strokes compared to medical therapy alone in patients with PFO-related strokes. This benefit is especially significant when the PFO carries high-risk features, such as a large shunt or the presence of an atrial septal aneurysm. Furthermore, the effectiveness of PFO closure has been well documented in young patients (<60 years) with a high-risk PFO development. In other cases, the therapeutic decision should be made through discussion among neurologists, cardiologists, and patients. Notably, in ESUS patients without a PFO, the underlying heart condition itself may be the source of embolism, with left atrial enlargement being the most important factor. Theoretically, anticoagulants such as non-vitamin K antagonist oral anticoagulants (NOACs) would be an effective therapy in these cases. However, recent trials have failed to show that NOACs are superior to antiplatelets in preventing further strokes in these patients. This may be due to the still uncertain definition of emboligenic cardiopathy and the presence of other potential embolic sources, such as mild but emboligenic arterial diseases. Overall, further research is needed to elucidate the source of embolism and to determine an effective management strategy for patients with ESUS.

Keyword

Stroke; Embolism; Embolic stroke with unknown source; Patent foramen ovale; Anticoagulation

Reference

References

1. Fonseca AC, Ferro JM. Cryptogenic stroke. Eur J Neurol. 2015; 22:618–623.

2. Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke. 2009; 40:2349–2355.

3. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24:35–41.

4. Yang H, Nassif M, Khairy P, de Groot JR, Roos YBWEM, de Winter RJ, et al. Cardiac diagnostic work-up of ischaemic stroke. Eur Heart J. 2018; 39:1851–1860.

5. Bang OY, Lee MJ, Ryoo S, Kim SJ, Kim JW. Patent foramen ovale and stroke-current status. J Stroke. 2015; 17:229–237.

6. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology. 2000; 55:1172–1179.

7. De Castro S, Cartoni D, Fiorelli M, Rasura M, Anzini A, Zanette EM, et al. Morphological and functional characteristics of patent foramen ovale and their embolic implications. Stroke. 2000; 31:2407–2413.

8. Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med. 2001; 345:1740–1746.

9. Falanga G, Carerj S, Oreto G, Khandheria BK, Zito C. How to understand patent foramen ovale clinical significance: part I. J Cardiovasc Echogr. 2014; 24:114–121.

10. Zoghbi WA. Patent foramen ovale: going beyond the bubbles. J Am Coll Cardiol Img. 2014; 7:251–253.

11. Mojadidi MK, Roberts SC, Winoker JS, Romero J, GoodmanMeza D, Gevorgyan R, et al. Accuracy of transcranial Doppler for the diagnosis of intracardiac right-to-left shunt: a bivariate meta-analysis of prospective studies. JACC Cardiovasc Imaging. 2014; 7:236–250.

12. Sorensen SG, Aguilar H, McKnight WK, Thomas H, Muhlestein JB. Transcranial Doppler quantification of residual shunt after percutaneous patent foramen ovale closure. Comparison of two devices. J Interv Cardiol. 2010; 23:575–580.

13. Wöhrle J. Closure of patent foramen ovale after cryptogenic stroke. Lancet. 2006; 368:350–352.

14. Katsanos AH, Spence JD, Bogiatzi C, Parissis J, Giannopoulos S, Frogoudaki A, et al. Recurrent stroke and patent foramen ovale: a systematic review and meta-analysis. Stroke. 2014; 45:3352–3359.

15. Prefasi D, Martínez-Sánchez P, Fuentes B, Díez-Tejedor E. The utility of the RoPE score in cryptogenic stroke patients ≤50 years in predicting a stroke-related patent foramen ovale. Int J Stroke. 2016; 11:NP7–NP8.

16. Kim JS, Hong KS. Patent foramen ovale closure: opportunity closed in old patients? J Stroke. 2021; 23:147–148.

17. Patti G, Pelliccia F, Gaudio C, Greco C. Meta-analysis of net long-term benefit of different therapeutic strategies in patients with cryptogenic stroke and patent foramen ovale. Am J Cardiol. 2015; 115:837–843.

18. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012; 366:991–999.

19. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013; 368:1092–1100.

20. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013; 368:1083–1091.

21. Kent DM, Dahabreh IJ, Ruthazer R, Furlan AJ, Reisman M, Carroll JD, et al. Device closure of patent foramen ovale after stroke: pooled analysis of completed randomized trials. J Am Coll Cardiol. 2016; 67:907–917.

22. Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017; 377:1022–1032.

23. Søndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017; 377:1033–1042.

24. Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017; 377:1011–1021.

25. Ntaios G, Papavasileiou V, Sagris D, Makaritsis K, Vemmos K, Steiner T, et al. Closure of patent foramen ovale versus medical therapy in patients with cryptogenic stroke or transient ischemic attack: updated systematic review and meta-analysis. Stroke. 2018; 49:412–418.

26. Mas JL, Saver JL, Kasner SE, Nelson J, Carroll JD, Chatellier G, et al. Association of atrial septal aneurysm and shunt size with stroke recurrence and benefit from patent foramen ovale closure. JAMA Neurol. 2022; 79:1175–1179.

27. Kent DM, Saver JL, Kasner SE, Nelson J, Carroll JD, Chatellier G, et al. Heterogeneity of treatment effects in an analysis of pooled individual patient data from randomized trials of device closure of patent foramen ovale after stroke. JAMA. 2021; 326:2277–2286.

28. Pristipino C, Sievert H, D’Ascenzo F, Louis Mas J, Meier B, Scacciatella P, et al. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. Eur Heart J. 2019; 40:3182–3195.

29. Alperi A, Guedeney P, Horlick E, Nombela-Franco L, Freixa X, Pascual I, et al. Transcatheter closure of patent foramen ovale in older patients with cryptogenic thromboembolic events. Circ Cardiovasc Interv. 2022; 15:e011652.

30. Krishnamurthy Y, Ben-Ami J, Robbins BT, Sommer RJ. Incidence and time course of atrial fibrillation following patent foramen ovale closure. Catheter Cardiovasc Interv. 2022; 100:219–224.

31. Badoz M, Derimay F, Serzian G, Besutti M, Rioufol G, Frey P, et al. Incidence of atrial fibrillation in cryptogenic stroke with patent foramen ovale closure: protocol for the prospective, observational PFO-AF study. BMJ Open. 2023; 13:e074584.

32. Messé SR, Gronseth GS, Kent DM, Kizer JR, Homma S, Rosterman L, et al. Practice advisory update summary: patent foramen ovale and secondary stroke prevention: report of the Guideline Subcommittee of the American Academy of Neurology. Neurology. 2020; 94:876–885.

33. Mazzucco S, Li L, Rothwell PM. Prognosis of cryptogenic stroke with patent foramen ovale at older ages and implications for trials: a population-based study and systematic review. JAMA Neurol. 2020; 77:1279–1287.

34. Lee PH, Song JK, Kim JS, Heo R, Lee S, Kim DH, et al. Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial. J Am Coll Cardiol. 2018; 71:2335–2342.

35. Kwon H, Lee PH, Song JK, Kwon SU, Kang DW, Kim JS. Patent foramen ovale closure in old stroke patients: a subgroup analysis of the DEFENSE-PFO trial. J Stroke. 2021; 23:289–292.

36. Lee PH, Kim JS, Song JK, Kwon SU, Kim BJ, Lee JS, et al. Device closure or antithrombotic therapy after cryptogenic stroke in elderly patients with a high-risk patent foramen ovale. J Stroke. 2024; 26:242–251.

37. Wang AY, Rothwell PM, Nelson J, Saver JL, Kasner SE, Carroll J, et al. Patent foramen ovale closure in older patients with stroke: patient selection for trial feasibility. Neurology. 2024; 102:e209388.

38. Kim JS, Thijs V, Yudi M, Toyoda K, Shiozawa M, Zening J, et al. Establishment of the heart and brain team for patent foramen ovale closure in stroke patients: an expert opinion. J Stroke. 2022; 24:345–351.

39. Stalikas N, Doundoulakis I, Karagiannidis E, Kartas A, Gavriilaki M, Sofidis G, et al. Prevalence of markers of atrial cardiomyopathy in embolic stroke of undetermined source: a systematic review. Eur J Intern Med. 2022; 99:38–44.

40. Jalini S, Rajalingam R, Nisenbaum R, Javier AD, Woo A, Pikula A. Atrial cardiopathy in patients with embolic strokes of unknown source and other stroke etiologies. Neurology. 2019; 92:e288–e294.

41. Kamel H, Okin PM, Merkler AE, Navi BB, Campion TR, Devereux RB, et al. Relationship between left atrial volume and ischemic stroke subtype. Ann Clin Transl Neurol. 2019; 6:1480–1486.

42. Kamel H, Okin PM, Elkind MS, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke. 2016; 47:895–900.

43. Lee YK, Gwak BC, Yoon BA, Kim DH, Cha JK. Atrial cardiopathy biomarkers and MRI-based infarct patterns in patients with embolic strokes of undetermined source. J Stroke Cerebrovasc Dis. 2021; 30:105933.

44. Benjamin EJ, D’Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation. 1995; 92:835–841.

45. Tsang TS, Abhayaratna WP, Barnes ME, Miyasaka Y, Gersh BJ, Bailey KR, et al. Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter? J Am Coll Cardiol. 2006; 47:1018–1023.

46. Edwards JD, Healey JS, Fang J, Yip K, Gladstone DJ. Atrial cardiopathy in the absence of atrial fibrillation increases risk of ischemic stroke, incident atrial fibrillation, and mortality and improves stroke risk prediction. J Am Heart Assoc. 2020; 9:e013227.

47. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005; 18:1440–1463.

48. Overvad TF, Nielsen PB, Larsen TB, Søgaard P. Left atrial size and risk of stroke in patients in sinus rhythm. A systematic review. Thromb Haemost. 2016; 116:206–219.

49. Bakalli A, Georgievska-Ismail L, Koçinaj D, Musliu N, Krasniqi A, Pllana E. Prevalence of left chamber cardiac thrombi in patients with dilated left ventricle at sinus rhythm: the role of transesophageal echocardiography. J Clin Ultrasound. 2013; 41:38–45.

50. Katayama T, Fujiwara N, Tsuruya Y. Factors contributing to left atrial enlargement in adults with normal left ventricular systolic function. J Cardiol. 2010; 55:196–204.

51. Arboix A, Alió J. Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis. Curr Cardiol Rev. 2010; 6:150–161.

52. Ruwald MH, Solomon SD, Foster E, Kutyifa V, Ruwald AC, Sherazi S, et al. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial. Circulation. 2014; 130:2278–2286.

53. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation. 1994; 89:724–730.

54. Tsang TS, Barnes ME, Bailey KR, Leibson CL, Montgomery SC, Takemoto Y, et al. Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. Mayo Clin Proc. 2001; 76:467–475.

55. Rizzo AC, Schwarz G, Bonelli A, Di Pietro A, Di Pietro M, Aruta F, et al. The role of atrial cardiopathy as a potential cause of embolic stroke of undetermined source. J Stroke. 2024; 26:330–334.

56. Healey JS, Gladstone DJ, Swaminathan B, Eckstein J, Mundl H, Epstein AE, et al. Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: secondary analysis of the NAVIGATE ESUS randomized clinical trial. JAMA Neurol. 2019; 76:764–773.

57. Geisler T, Keller T, Martus P, Poli K, Serna-Higuita LM, Schreieck J, et al. Apixaban versus aspirin for embolic stroke of undetermined source. NEJM Evid. 2024; 3:EVIDoa2300235.

58. Kamel H, Longstreth WT Jr, Tirschwell DL, Kronmal RA, Broderick JP, Palesch YY, et al. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: rationale and methods. Int J Stroke. 2019; 14:207–214.

59. Kamel H, Longstreth WT Jr, Tirschwell DL, Kronmal RA, Marshall RS, Broderick JP, et al. Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: the ARCADIA randomized clinical trial. JAMA. 2024; 331:573–581.

60. Kamel H, Soliman EZ, Heckbert SR, Kronmal RA, Longstreth WT Jr, Nazarian S, et al. P-wave morphology and the risk of incident ischemic stroke in the multi-ethnic study of atherosclerosis. Stroke. 2014; 45:2786–2788.

61. Folsom AR, Nambi V, Bell EJ, Oluleye OW, Gottesman RF, Lutsey PL, et al. Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study. Stroke. 2013; 44:961–967.

62. Maheshwari A, Norby FL, Inciardi RM, Wang W, Zhang MJ, Soliman EZ, et al. Left atrial mechanical dysfunction and the risk for ischemic stroke in people without prevalent atrial fibrillation or stroke: a prospective cohort study. Ann Intern Med. 2023; 176:39–48.

63. Veltkamp R, Pearce LA, Korompoki E, Sharma M, Kasner SE, Toni D, et al. Characteristics of recurrent ischemic stroke after embolic stroke of undetermined source: secondary analysis of a randomized clinical trial. JAMA Neurol. 2020; 77:1233–1240.

64. Ospel JM, Marko M, Singh N, Goyal M, Almekhlafi MA. Prevalence of non-stenotic (<50%) carotid plaques in acute ischemic stroke and transient ischemic attack: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2020; 29:105117.

65. Ospel JM, Singh N, Marko M, Almekhlafi M, Dowlatshahi D, Puig J, et al. Prevalence of ipsilateral nonstenotic carotid plaques on computed tomography angiography in embolic stroke of undetermined source. Stroke. 2020; 51:1743–1749.

66. Kamtchum-Tatuene J, Wilman A, Saqqur M, Shuaib A, Jickling GC. Carotid plaque with high-risk features in embolic stroke of undetermined source: systematic review and meta-analysis. Stroke. 2020; 51:311–314.

67. Sakai Y, Lehman VT, Eisenmenger LB, Obusez EC, Kharal GA, Xiao J, et al. Vessel wall MR imaging of aortic arch, cervical carotid and intracranial arteries in patients with embolic stroke of undetermined source: a narrative review. Front Neurol. 2022; 13:968390.

68. Tao L, Dai YJ, Shang ZY, Li XQ, Wang XH, Ntaios G, et al. Atrial cardiopathy and non-stenotic intracranial complicated atherosclerotic plaque in patients with embolic stroke of undetermined source. J Neurol Neurosurg Psychiatry. 2022; 93:351–359.

69. Park HK, Kim BJ, Yoon CH, Yang MH, Han MK, Bae HJ. Left ventricular diastolic dysfunction in ischemic stroke: functional and vascular outcomes. J Stroke. 2016; 18:195–202.

70. Kuznetsova T, Herbots L, López B, Jin Y, Richart T, Thijs L, et al. Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail. 2009; 2:105–112.

71. Hays AG, Sacco RL, Rundek T, Sciacca RR, Jin Z, Liu R, et al. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke. 2006; 37:1715–1719.

72. Takasugi J, Yamagami H, Noguchi T, Morita Y, Tanaka T, Okuno Y, et al. Detection of left ventricular thrombus by cardiac magnetic resonance in embolic stroke of undetermined source. Stroke. 2017; 48:2434–2440.

73. Ramasamy S, Yaghi S, Salehi Omran S, Lerario MP, Devereux R, Okin PM, et al. Association between left ventricular ejection fraction, wall motion abnormality, and embolic stroke of undetermined source. J Am Heart Assoc. 2019; 8:e011593.

74. Choi JY, Cha J, Jung JM, Seo WK, Oh K, Cho KH, et al. Left ventricular wall motion abnormalities are associated with stroke recurrence. Neurology. 2017; 88:586–594.

75. Merkler AE, Pearce LA, Kasner SE, Shoamanesh A, Birnbaum LA, Kamel H, et al. Left ventricular dysfunction among patients with embolic stroke of undetermined source and the effect of rivaroxaban vs aspirin: a subgroup analysis of the NAVIGATE ESUS randomized clinical trial. JAMA Neurol. 2021; 78:1454–1460.